0.772

4.04% -0.0354

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $0.772, with a volume of 727.83K. It is down -4.04% in the last 24 hours and down -8.69% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$0.8074

Open:

$0.79

24h Volume:

727.83K

Relative Volume:

0.20

Market Cap:

$122.28M

Revenue:

$126.33M

Net Income/Loss:

$-82.68M

P/E Ratio:

-0.6226

EPS:

-1.24

Net Cash Flow:

$-79.98M

1W Performance:

+0.48%

1M Performance:

-8.69%

6M Performance:

-33.21%

1Y Performance:

-40.40%

1-Day Range:

$0.76

$0.82

1-Week Range:

$0.7511

$0.8482

52-Week Range:

$0.54

$2.05

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

233

Twitter

@SeresTX

Next Earnings Date

2024-10-31

Latest SEC Filings

MCRB's Discussions on Twitter

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

Oct 30, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com - Investing.com Australia

Oct 30, 2024

Seres Therapeutics exec von Moltke sells $2,991 in stock - Investing.com India

Oct 30, 2024

Seres Therapeutics exec von Moltke sells $2,991 in stock By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 By Investing.com - Investing.com Canada

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 - Investing.com India

Oct 29, 2024

Seres Therapeutics executive sells stock for $2,749 By Investing.com - Investing.com Australia

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock By Investing.com - Investing.com South Africa

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock - Investing.com India

Oct 29, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock - Investing.com India

Oct 29, 2024

Oct 26, 2024

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St

Oct 26, 2024

Oct 24, 2024

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN

Oct 24, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $5.08 Consensus Price Target from Analysts - MarketBeat

Oct 24, 2024

Seres Therapeutics (NASDAQ:MCRB) Stock Rating Lowered by JPMorgan Chase & Co. - MarketBeat

Oct 24, 2024

Oct 23, 2024

Seres cut to underweight by JP Morgan on Vowst sale - MSN

Oct 23, 2024

Seres cut to underweight by JP Morgan on Vowst sale (NASDAQ:MCRB) - Seeking Alpha

Oct 23, 2024

Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Oct 21, 2024

Oct 16, 2024